Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a clinical study titled ‘A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and optimal dosing of REGN7075, alone and in combination with cemiplimab, for treating advanced solid tumors. This research is significant as it explores new treatment avenues for difficult-to-treat cancers.
The study is testing the investigational drug REGN7075, which is administered either intravenously or subcutaneously, and cemiplimab, both of which are intended to enhance the immune system’s ability to fight cancer.
This interventional study is non-randomized and follows a sequential intervention model without masking, focusing primarily on treatment. It is designed to assess the efficacy and safety of the drug combinations in various cancer types.
The study began on November 6, 2020, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 29, 2025, indicating ongoing progress.
The outcomes of this study could significantly impact Regeneron’s stock performance by potentially introducing a new cancer treatment to the market. This development may also influence investor sentiment positively, given the competitive landscape of cancer therapeutics.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.